These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

816 related articles for article (PubMed ID: 30086764)

  • 1. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
    Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
    Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
    Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
    Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
    Ross JS; Ali SM; Wang K; Khaira D; Palma NA; Chmielecki J; Palmer GA; Morosini D; Elvin JA; Fernandez SV; Miller VA; Stephens PJ; Cristofanilli M
    Breast Cancer Res Treat; 2015 Nov; 154(1):155-62. PubMed ID: 26458824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of germline variants in inflammatory breast cancer.
    Rana HQ; Sacca R; Drogan C; Gutierrez S; Schlosnagle E; Regan MM; Speare V; LaDuca H; Dolinsky J; Garber JE; Overmoyer BA
    Cancer; 2019 Jul; 125(13):2194-2202. PubMed ID: 30933323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
    Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
    Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors.
    Hamm CA; Moran D; Rao K; Trusk PB; Pry K; Sausen M; Jones S; Velculescu VE; Cristofanilli M; Bacus S
    Mol Cancer Ther; 2016 Jul; 15(7):1746-56. PubMed ID: 27196778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC).
    Gong Y; Nagarathinam R; Arisi MF; Gerratana L; Winn JS; Slifker M; Pei J; Cai KQ; Hasse Z; Obeid E; Noriega J; Sebastiano C; Ross E; Alpaugh K; Cristofanilli M; Fernandez SV
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MARCKS protein overexpression in inflammatory breast cancer.
    Manai M; Thomassin-Piana J; Gamoudi A; Finetti P; Lopez M; Eghozzi R; Ayadi S; Lamine OB; Manai M; Rahal K; Charafe-Jauffret E; Jacquemier J; Viens P; Birnbaum D; Boussen H; Chaffanet M; Bertucci F
    Oncotarget; 2017 Jan; 8(4):6246-6257. PubMed ID: 28009981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic alterations in sporadic triple negative breast cancer.
    Pop LA; Cojocneanu-Petric RM; Pileczki V; Morar-Bolba G; Irimie A; Lazar V; Lombardo C; Paradiso A; Berindan-Neagoe I
    Breast; 2018 Apr; 38():30-38. PubMed ID: 29202330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609).
    Liang X; Briaux A; Becette V; Benoist C; Boulai A; Chemlali W; Schnitzler A; Baulande S; Rivera S; Mouret-Reynier MA; Bouvet LV; De La Motte Rouge T; Lemonnier J; Lerebours F; Callens C
    J Hematol Oncol; 2018 Oct; 11(1):124. PubMed ID: 30305115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers.
    Li X; Kumar S; Harmanci A; Li S; Kitchen RR; Zhang Y; Wali VB; Reddy SM; Woodward WA; Reuben JM; Rozowsky J; Hatzis C; Ueno NT; Krishnamurthy S; Pusztai L; Gerstein M
    Genome Med; 2021 Apr; 13(1):70. PubMed ID: 33902690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NGS-based oncogenic mutations analysis in advanced colorectal cancer patients improves targeted therapy prediction.
    Li W; Qiu T; Guo L; Ying J; Zhou A
    Pathol Res Pract; 2019 Mar; 215(3):483-489. PubMed ID: 30611619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis.
    Jiao D; Zhang J; Zhu J; Guo X; Yang Y; Xiao H; Liu Z
    BMC Cancer; 2021 Feb; 21(1):138. PubMed ID: 33549037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic EP300-G211S mutations are associated with overall somatic mutational patterns and breast cancer specific survival in triple-negative breast cancer.
    Bemanian V; Noone JC; Sauer T; Touma J; Vetvik K; Søderberg-Naucler C; Lindstrøm JC; Bukholm IR; Kristensen VN; Geisler J
    Breast Cancer Res Treat; 2018 Nov; 172(2):339-351. PubMed ID: 30132219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
    Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
    Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing.
    Roy-Chowdhuri S; de Melo Gagliato D; Routbort MJ; Patel KP; Singh RR; Broaddus R; Lazar AJ; Sahin A; Alvarez RH; Moulder S; Wheler JJ; Janku F; Gonzalez-Angulo AM; Chavez-MacGregor M; Valero V; Ueno NT; Mills G; Mendelsohn J; Yao H; Aldape K; Luthra R; Meric-Bernstam F
    Am J Clin Pathol; 2015 Nov; 144(5):713-21. PubMed ID: 26486734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
    Lee S; Kim HY; Jung YJ; Jung CS; Im D; Kim JY; Lee SM; Oh SH
    Curr Probl Cancer; 2022 Apr; 46(2):100843. PubMed ID: 35180531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of frequent somatic mutations in inflammatory breast cancer.
    Matsuda N; Lim B; Wang Y; Krishnamurthy S; Woodward W; Alvarez RH; Lucci A; Valero V; Reuben JM; Meric-Bernstam F; Ueno NT
    Breast Cancer Res Treat; 2017 Jun; 163(2):263-272. PubMed ID: 28243898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
    Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
    Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
    Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
    BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.